About RedHill

RedHill Biopharma Ltd. (NASDAQ/TASE: RDHL) is a specialty biopharmaceutical company primarily focused on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of gastrointestinal and inflammatory diseases, including cancer.

The Company’s current product pipeline includes:

RHB-105 - An oral combination therapy for Helicobacter pylori infection, with positive results from a first Phase III study. 

RHB-104 - An oral combination therapy for the treatment of Crohn's disease with an ongoing first Phase III study, a completed proof-of-concept Phase IIa study for multiple sclerosis, and QIDP status for nontuberculous mycobacteria (NTM) infections.

BEKINDA® (RHB-102) - A once-daily oral pill formulation of ondansetron with an ongoing Phase III study for acute gastroenteritis and gastritis and an ongoing Phase II study for IBS-D.

RHB-106 - An encapsulated formulation for bowel preparation licensed to Salix Pharmaceuticals Ltd.

YELIVA® (ABC294640) - A Phase II-stage, orally-administered, first-in-class SK2 selective inhibitor targeting multiple oncology, inflammatory and gastrointestinal indications

MESUPRON - A Phase II-stage, orally-administered, first-in-class protease inhibitor targeting pancreatic cancer and other solid tumor cancers. 

RIZAPORT® (RHB-103) - An oral thin film formulation of rizatriptan, for the treatment of acute migraines, with a U.S. NDA currently under discussion with the FDA and marketing authorization received in Germany in October 2015.

RedHill also has a U.S. co-promotion agreement with a subsidiary of Concordia International Corp. (NASDAQ: CXRX) (TSX: CXR) for Donnatal®, a prescription oral adjunctive drug used in the treatment of IBS and acute enterocolitis.